# Butterfly Network, Inc.: Form 10-Q for the period ended Mar 31, 2021

- Company: [Butterfly Network, Inc.](/companies/bfly.md) (CIK 1804176)
- Form: 10-Q
- Filed: 2021-05-17
- Accepted by EDGAR: May 17, 2021, 16:14 ET
- Period: 2021-03-31
- Accession: 0001558370-21-007403
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1804176/000155837021007403/tmb-20210331x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1804176/000155837021007403/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-01-01 to 2021-03-31 | $12.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2021-01-01 to 2021-03-31 | $6.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2021-01-01 to 2021-03-31 | $6.4m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-01-01 to 2021-03-31 | $15.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-01-01 to 2021-03-31 | −$53.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-01-01 to 2021-03-31 | $638.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-01-01 to 2021-03-31 | $24.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-01-01 to 2021-03-31 | −$690.0k | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months, 2021-01-01 to 2021-03-31 | −$63.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2021-01-01 to 2021-03-31 | $1.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-03-31 | $18.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-03-31 | $605.2m | us-gaap:AssetsCurrent |
| Total assets | at 2021-03-31 | $647.5m | us-gaap:Assets |
| Current liabilities | at 2021-03-31 | $52.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-03-31 | $211.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-03-31 | $436.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 40,740 characters.

*The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations and financial condition. The discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto contained in this Quarterly Report on Form 10-Q and the consolidated financial statements and notes thereto for the year ended December 31, 2020 contained in Amendment No. 2 to the Current Report on Form 8-K filed with the SEC on March 29, 2021. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2020, as amended, and of this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our”, and “the Company” are intended to mean the business and operations of Butterfly Network, Inc. and its consolidated subsidiaries. The unaudited condensed consolidated financial statements for the three months ended March 31, 2021 and 2020, respectively, present the financial position and results of operations of Butterfly Network, Inc. and its wholly-owned subsidiaries.*

### Overview

We are an innovative digital health business whose mission is to democratize healthcare by making medical imaging accessible to everyone around the world. Powered by our proprietary Ultrasound-on-Chip™ technology, our solution uses a unique combination of software and hardware to address the needs of point-of-care imaging. Butterfly iQ, followed by our recently launched Butterfly iQ+, is our first product powered by Butterfly’s Ultrasound-on-Chip™, and is the only ultrasound transducer that can perform “whole-body imaging” in a single handheld probe using semiconductor technology. Our Ultrasound-on-Chip™ reduces the cost of manufacturing, while our software is intended to make the product easy to use and fully integrated with the clinical workflow, accessible on a user’s smartphone, tablet, and almost any hospital computer system connected to the Internet. Through our portable proprietary, handheld solution, protected by a robust intellectual property portfolio and empowered in part by its proprietary software and Artificial Intelligence (“AI”), Butterfly aims to enable earlier detection throughout the body and remote management of health conditions around the world.

The Butterfly iQ / iQ+ is currently cleared by the U.S. Food and Drug Administration (“FDA”) and has the CE mark for use by health care practitioners. It is commercially available in over 20 countries including, the United States, Canada, Australia, New Zealand and throughout greater Europe.

We are focused on driving the adoption of our handheld solution. We look to drive adoption by increasing the touchpoints with our customer, through new sales channels, as well as helping customers understand the power of point of care imaging in clinical decision making expanding its use cases and the settings where it is used. We also invest in upgrading our product. In October 2020, we launched the Butterfly iQ+, a second-generation version of our handheld probe which costs less to manufacture and features lower power consumption, faster frame rates and improved interoperability. Additionally, over the course of 2021, we launched multiple new software features that improve image acquisition and ease of use.

We are also focused on improving gross profits by focusing on operational efficiencies in our supply chain and expanding our customer relationships to incorporate higher margin products and services.

### COVID-19

In December 2019, a novel coronavirus outbreak and related disease (known as COVID-19) was identified in Wuhan, China. In March 2020 the World Health Organization declared the outbreak of COVID-19 a pandemic. We are closely monitoring the impact of COVID-19 on all aspects of our business.

COVID-19 has disrupted, and we believe will continue to disrupt, our normal operations. There have been both positive and negative impacts, some quantifiable and others not quantifiable based on our limited historical data as an emerging growth company. Therefore, it is difficult for us to quantify the overall impact of the COVID-19 pandemic on our revenues.

In order to improve our liquidity during the COVID-19 pandemic, we obtained a loan under the Paycheck Protection Program (the “PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. We repaid the PPP loan in full in February 2021 from the proceeds of the Business Combination.

In terms of negative impacts, the pandemic has restricted the ability of our employees to travel, demonstrate our products to our potential customers and users, and perform other sales-generating activities. It has also impacted our ability to oversee the activities of our third-party manufacturers and suppliers, make shipments of materials, and pursue collaborations and other business transactions. COVID-19 has also caused the temporary closure of the facilities of certain of our suppliers, manufacturers and customers, and resulted in the implementation of a temporary closure of our offices and the institution of a “work from home” policy. In addition, the COVID-19 pandemic and its economic impact have caused a financial strain on our customer base due to decreased funding and other revenue shortfalls. Reductions in budgets have resulted in delays in or decreases in the size of enterprise contracts. Given the lack of historical trends, we are unable to precisely quantify this impact.

Conversely, given those restrictions of access to our customers and “work from home” policy, one noticeable and quantifiable positive impact on our expenses was the reduction in our travel and related expenses, which for the quarter ended March 31, 2021 decreased by approximately $0.4 million, or 71%, year over year.

The COVID-19 pandemic also had a short-term early positive impact on our sales. We saw a spike in orders in March and April of 2020 because point-of-care ultrasound systems, like Butterfly iQ, have been utilized in the monitoring of acute symptoms of COVID-19 in patients through the use of lung ultrasound. Studies suggest that such systems may have a role to play in the assessment of lung involvement in COVID-19. The Butterfly iQ’s lung image quality, portability and ease of disinfection has made it particularly useful in assessing patients impacted by COVID-19. Given the lack of historical trends, we are unable to precisely quantify this impact.

The estimates of the impact on our business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.

Despite these headwinds, we believe our business is well-positioned to benefit from the trends, such as telemedicine, that are accelerating digital transformation of the healthcare industry as a result of the COVID-19 pandemic. For instance, we have developed a Teleguidance product that aligns with the larger industry trends to remote medicine. Additionally, we believe that our value proposition of improved patient care combined with a reduction in overall cost of service will further enhance adoption of the Butterfly solution.

We have not incurred any significant impairment losses in the carrying values of our assets as a result of the COVID-19 pandemic and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in our condensed consolidated financial statements contained in this Form 10-Q.

### Recent Developments

On February 12, 2021 we completed the business combination with Longview (the “Business Combination”) pursuant to the terms of the Business Combination Agreement, dated as of November 19, 2020 (the “Business Combination Agreement”), by and among Longview Acquisition Corp. (“Longview”), Clay Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Butterfly Network, Inc., a Delaware corporation (“Legacy Butterfly”). The Business Combination was approved by Longview's stockholders at its special meeting held on February 12, 2021. The transaction resulted in the Company being renamed to "Butterfly Network, Inc.," Legacy Butterfly being renamed “BFLY Operations, Inc.” and the Company’s Class A common stock and warrants to purchase Class A common stock commencing trading on the New York Stock Exchange ("NYSE") on February 16, 2021 under the symbol "BFLY" and “BFLY WS”, respectively. As a result of the Business Combination, we received gross proceeds of approximately $589 million.

### Key Performance Metrics

We review the key performance measures discussed below, to evaluate business and measure performance, identify trends, formulate plans and make strategic decisions.

### Units fulfilled

We define units fulfilled as the number of devices whereby control is transferred to a customer. We do not adjust this metric for returns as our volume of returns has historically been low. We view units fulfilled as a key indicator of the growth of our business. We believe that this metric is useful to investors because it presents our core growth and performance of our business period over period.

| ​ ​ ​ ​ ​ ​ | ​ ​ Three months ended March 31, 2021 ​ | ​ 2020 |
| --- | ---: | ---: |
| Units fulfilled | 5,013 | 3,711 |

Units fulfilled increased by 1,302, or 35.1%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020, primarily due to increased demand driven by additional investment in lead generation.

### Subscription Mix

We define subscription mix as a percentage of our total revenue recognized in a reporting period that is subscription based, consisting primarily of our software as a service (“SaaS”) offering. We view subscription mix as a key indicator of the profitability of our business, and thus we believe that this metric is useful to investors. Because the costs and associated expenses to deliver our subscription offerings are lower as a percentage of sales than the costs of sales of our products, we believe a shift towards subscription will result in an improvement in profitability and margin expansion.

| ​ ​ ​ ​ ​ ​ | ​ ​ Three months ended March 31, 2021 | ​ ​ 2020 |
| --- | ---: | ---: |
| Subscription mix | 22.9% | 16.9% |

Subscription mix increased by 6.0 percentage points, to 22.9% for the three months ended March 31, 2021 compared to the three months ended March 31, 2020, due to increased volume of device sales and increases in subscription renewals, as well as the timing of revenue recognition for our SaaS and other subscription contracts. Revenue from such contracts is deferred and recognized over the service period.

### Non-GAAP Financial Measures

We present non-GAAP financial measures in order to assist readers of our condensed consolidated financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes. Our non-GAAP financial measures, Adjusted Gross Profit and Adjusted EBITDA, provide an additional tool for investors to use in comparing our financial performance over multiple periods.

Adjusted Gross Profit and Adjusted EBITDA are key performance measures that our management uses to assess our operating performance. Adjusted Gross Profit and Adjusted EBITDA facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that Adjusted Gross Profit and Adjusted EBITDA enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.

Our Adjusted Gross Profit and Adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. Adjusted Gross Profit and Adjusted EBITDA are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating our performance, you should consider Adjusted Gross Profit and Adjusted EBITDA alongside other financial performance measures prepared in accordance with GAAP, including gross profit, operating loss, and net loss.

### Adjusted Gross Profit

We calculate Adjusted Gross Profit as gross profit adjusted to exclude depreciation and amortization and non-recurring changes to our warranty liability. Our changes in the warranty liability are excluded from gross profit when they are outside the normal course of operations for our business. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.

The following table reconciles Adjusted Gross Profit to gross profit, the most directly comparable financial measure calculated and presented in accordance with GAAP.

| ​ ​ ​ | ​ ​ ​ | ​ ​ Three months ended March 31, 2021 | ​ ​ | ​ ​ 2020 | ​ ​ ​ |
| --- | --- | ---: | --- | ---: | --- |
| Revenue |  | $12,443 |  | $8,670 | ​ |
| Cost of revenue | ​ | 6,027 | ​ | 9,506 | ​ |
| Gross profit | ​ | $6,416 | ​ | $(836) | ​ |
| Add: | ​ |  | ​ |  | ​ |
| Depreciation and amortization | ​ | 89 | ​ | 22 | ​ |
| Warranty liability policy change | ​ | ​ (560) | ​ | ​ — | ​ |
| **Adjusted gross profit** | **​** | **$5,945** | **​** | **$(814)** | **​** |

### Adjusted EBITDA

We calculate Adjusted EBITDA as net loss adjusted to exclude interest income, interest expense, other expense, net, provision for income taxes, depreciation and amortization, stock-based compensation, changes in the fair value of warrant liabilities and other non-recurring items. The other non-recurring items include costs related to our executive transition, discretionary transaction bonuses and other fees incurred with the close of the Business Combination and adjustments for the warranty liability policy changes. Our non-recurring discretionary bonuses are excluded from Adjusted EBITDA when they are outside the normal course of operations for our business and were given at the discretion of management due to the completion of the Business Combination. The non-recurring costs related to the executive transition include one-time severance and bonus payments and the recruiting expenses for our current CEO. The non-recurring warranty liability adjustments are for changes in our warranty policy resulting from a shift in product lines that impacted our estimate of future warranty costs.

The following table reconciles Adjusted EBITDA to net loss, the most directly comparable financial measure calculated and presented in accordance with GAAP.

*(In thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ Three months ended March 31, 2021 | ​ ​ | ​ ​ 2020 | ​ ​ ​ |
| --- | --- | --- | --- | --- | --- |
| **Net loss** |  | **$(690)** |  | **$(24,354)** | **​** |
| Interest income |  | ​ (239) |  | ​ (199) | ​ |
| Interest expense |  | ​ 638 |  | ​ 5 | ​ |
| Change in fair value of warrant liabilities | ​ | ​ (54,112) | ​ | ​ — | ​ |
| Other expense, net |  | ​ 631 |  | ​ 29 | ​ |
| Provision for income taxes |  | ​ 24 |  | ​ 10 | ​ |
| Stock based compensation |  | ​ 20,298 |  | ​ 2,683 | ​ |
| Depreciation and amortization |  | ​ 458 |  | ​ 285 | ​ |
| CEO transition costs | ​ | ​ 5,398 | ​ | ​ — | ​ |
| Warranty liability policy change | ​ | ​ (560) | ​ | ​ — | ​ |
| Transaction bonus | ​ | ​ 1,653 | ​ | ​ — | ​ |
| **Adjusted EBITDA** |  | **$(26,501)** |  | **$(21,541)** | **​** |

### Description of Certain Components of Financial Data

### Revenue

Revenue consists of revenue from the sale of products such as medical devices, accessories, and related services, classified as subscription revenue on our condensed consolidated statements of operations and comprehensive loss, which are SaaS subscriptions and Support. SaaS subscriptions include licenses for teams and individuals as well as enterprise level subscriptions. For sales of products (which include the ultrasound devices and any ultrasound device accessories), revenue is recognized at a point in time upon transfer of control to the customer. SaaS subscriptions and Support are generally related to stand-ready obligations and are recognized ratably over time.

Our product sales generate approximately 77.1% of our revenue, with our SaaS subscription revenue comprising the remaining 22.9%. As adoption of our devices increases through further market penetration and practitioners in the Butterfly network continue to use our devices, we expect our annual revenue mix to shift more toward subscriptions. The quarterly revenue mix may be impacted by the timing of device sales.

### Cost of revenue

Cost of product revenue consists of product costs, including manufacturing costs, personnel costs and benefits, inbound freight, packaging, warranty replacement costs, payment processing fees and inventory obsolescence and write-offs. We expect our cost of product revenue to fluctuate over time due to the level of units fulfilled in any given period and decrease as a percentage of revenues over time as we focus on operational efficiencies in our supply chain.

Cost of subscription revenue consists of personnel costs, cloud hosting costs and payment processing fees. Because the costs and associated expenses to deliver our SaaS offerings are less than the costs and associated expenses of manufacturing and selling our device, we anticipate a natural improvement in profitability and margin expansion over time as our mix shifts increasingly towards subscriptions.

We plan to continue to invest additional resources into our products to expand and further develop our offerings. The level and timing of investment in these areas could affect our cost of revenue in the future.

### Research and development (R&D)

Research and development expenses primarily consist of personnel costs and benefits, facilities-related expenses, depreciation expense, consulting and professional fees, fabrication services, software and other outsourcing expenses. Most of our research and development expenses are related to developing new products and services and improving existing products and services, which we define as not having reached the point of commercialization, and improving our products and services that have been commercialized. Consulting expenses are related to general development activities and clinical/regulatory research. Fabrication services include certain third-party engineering costs, product testing, and test boards. Research and development expenses are expensed as incurred. We expect to continue to make substantial investments in our product development, clinical and regulatory capabilities. Prospectively, we expect R&D spending as a percentage of revenues will increase in the near term and then fluctuate over time due to the level and timing of our new product development efforts.

### Sales and marketing

Sales and marketing expenses primarily consist of personnel costs and benefits, third party logistics, fulfillment and outbound shipping costs, digital marketing, advertising, promotional, as well as conferences, meetings and other events and related facilities and information technology costs. We expect our sales and marketing expenses to increase in absolute dollars in the long term as we continue to increase the size of our direct sales force and sales support personnel and expand into new products and markets. We expect our sales and marketing expenses will also increase in the near term as we promote our brand through marketing and advertising initiatives, expand market presence and hire additional personnel to drive penetration and generate leads. We expect that sales and marketing expenses as a percentage of revenues will increase in the near term and then fluctuate over time as we evaluate expansion opportunities.

### General and administrative

General and administrative expenses primarily consist of personnel costs and benefits, patent and filing fees, facilities costs, office expenses and outside services. Outside services consist of professional services, legal and other professional fees. We expect our general and administrative expenses to increase in absolute dollars in the foreseeable future. We anticipate general and administrative expenses as a percentage of revenues will increase in the near term and then fluctuate over time due to the timing and amount of these expenses. In addition, we expect to incur additional general and administrative expenses as a result of operating as a public company.

### Other income (expense), net

Other income (expense), net primarily consists of foreign exchange gains or losses and investment gains or losses.

### Provision for income taxes

Deferred tax assets are reduced by a valuation allowance to the extent management believes it is not more likely than not to be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. Management makes estimates and judgments about future taxable income based on assumptions that are consistent with our plans and estimates. We recorded a full valuation allowance as of March 31, 2021 and December 31, 2020. We expect that income tax expense will be due to operations in profitable foreign subsidiaries.

### Results of Operations

We operate as a single reportable segment to reflect the way our chief operating decision maker (“CODM”) reviews and assesses the performance of the business. The accounting policies are described in Note 2 in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

*(in thousands)*

| ​ ​ ​ ​ Revenue: | ​ ​ ​ ​ ​ | ​ ​ Three months ended March 31, 2021 ​ ​ Dollars ​ | ​ ​ ​ | ​ ​ ​ % of ​ revenue ​ | ​ ​ ​ ​ ​ | ​ ​ 2020 ​ ​ Dollars ​ | ​ ​ ​ | ​ ​ % of revenue ​ |
| --- | --- | --- | --- | ---: | --- | --- | --- | ---: |
| Product | ​ | $9,595 |  | 77.1% | ​ | $7,209 |  | 83.1% |
| Subscription | ​ | ​ 2,848 |  | 22.9% | ​ | ​ 1,461 |  | 16.9% |
| **Total revenue:** | ​ | $12,443 |  | 100.0% | ​ | $8,670 |  | 100.0% |
| Cost of revenue: | ​ | ​ |  |  | ​ | ​ |  | ​ |
| Product | ​ | ​ 5,648 |  | 45.4% | ​ | ​ 9,262 |  | 106.8% |
| Subscription | ​ | ​ 379 |  | 3.0% | ​ | ​ 244 |  | 2.8% |
| **Total cost of revenue:** | ​ | $6,027 |  | 48.4% | ​ | $9,506 |  | 109.6% |
| **Gross profit** | **​** | **$6,416** |  | 51.6% | ​ | **$(836)** |  | (9.6)% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Operating expenses: | ​ | ​ |  |  | ​ | ​ |  | ​ |
| Research and development | ​ | ​ 15,716 |  | 126.3% | ​ | ​ 12,516 |  | 144.4% |
| Sales and marketing | ​ | ​ 9,808 |  | 78.8% | ​ | ​ 5,915 |  | 68.2% |
| General and administrative | ​ | ​ 34,640 |  | 278.4% | ​ | ​ 5,242 |  | 60.5% |
| **Total operating expenses** | **​** | **$60,164** |  | 483.5% | ​ | **$23,673** |  | 273.0% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Loss from operations** | **​** | **$(53,748)** |  | (432.0)% | **​** | **$(24,509)** |  | (282.7)% |
| Interest income | ​ | ​ 239 |  | 1.9% | ​ | ​ 199 |  | 2.3% |
| Interest expense | ​ | ​ (638) |  | (5.1)% | ​ | ​ (5) |  | (0.1)% |
| Change in fair value of warrant liabilities | ​ | ​ 54,112 | ​ | 434.9% | ​ | ​ — | ​ | —% |
| Other income (expense), net | ​ | ​ (631) |  | (5.1)% | ​ | ​ (29) |  | (0.3)% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Loss before provision for income taxes** | **​** | **$(666)** |  | (5.4)% | ​ | **$(24,344)** |  | (280.8)% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| Provision for income taxes | ​ | ​ 24 |  | 0.2% | ​ | ​ 10 |  | 0.1% |
| ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ | ​ | ​ ​ |
| **Net loss** | **​** | **$(690)** |  | (5.5)% | ​ | **$(24,354)** |  | (280.9)% |

### Comparison of the three months ended March 31, 2021 and 2020

### Revenue

*(in thousands)*

| ​ ​ Revenue: | ​ ​ ​ | ​ ​ Three months ended March 31, 2021 ​ | ​ ​ | ​ ​ 2020 ​ | ​ ​ ​ | ​ ​ ​ ​ Change ​ | ​ ​ ​ ​ ​ ​ % Change ​ |
| --- | --- | ---: | --- | ---: | --- | ---: | ---: |
| Product |  | $9,595 | ​ | $7,209 | ​ | $2,386 | 33.1% |
| Subscription |  | ​ 2,848 | ​ | ​ 1,461 | ​ | ​ 1,387 | 94.9% |
| Total revenue: | ​ | $12,443 | ​ | $8,670 | ​ | $3,773 | 43.5% |

Total revenue increased by $3.8 million, or 43.5%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020.

Product revenue increased by $2.4 million, or 33.1%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase in product revenue was primarily driven by a higher volume of Butterfly iQ+ probes sold, as a result of our increased investment in our sales and marketing efforts.

Subscription revenue increased by $1.4 million, or 94.9%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was driven by an increased volume of our SaaS subscriptions sold in conjunction with sales of our devices as well as the increase from subscription renewals year over year.

### Cost of revenue

*(in thousands)*

| ​ ​ Cost of revenue: | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2021 ​ ​ | ​ ​ ​ ​ 2020 ​ ​ | ​ ​ ​ ​ Change ​ | ​ ​ ​ ​ ​ ​ % Change ​ |
| --- | --- | ---: | ---: | ---: | ---: |
| Product |  | $5,648 ​ | $9,262 ​ | $(3,614) | (39.0)% |
| Subscription |  | ​ 379 ​ | ​ 244 ​ | ​ 135 | 55.3% |
| Total cost of revenue | ​ | $6,027 ​ | $9,506 ​ | $(3,479) | (36.6)% |
| Percentage of revenue | ​ | 48.4% | 109.6% |  | ​ |

Cost of product revenue decreased by $3.6 million, or 39.0%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This decrease was driven by the sale of our second generation product, the Butterfly IQ+, in the quarter ended March 31, 2021 as opposed to the Butterfly IQ in the quarter ended March 31, 2020. The IQ+’s lower product cost and associated lower warranty cost primarily accounted for $2.9 million of the decrease in costs associated with product sales.

Cost of subscription revenue increased by $0.1 million, or 55.3%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily driven by increased cloud hosting costs.

### Research and development

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development |  | $15,716 | $12,516 | $3,200 | 25.6% |
| Percentage of revenue | ​ | 126.3% | 144.4% |  | ​ |

Research and development expenses increased by $3.2 million, or 25.6%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily driven by increased personnel costs of $3.8 million as we continue to invest in expanding our internal research capabilities. These expenses were partially offset by a decrease in spending on fabrication services of $0.6 million.

### Sales and marketing

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Sales and marketing |  | $9,808 | $5,915 | $3,893 | 65.8% |
| Percentage of revenue | ​ | 78.8% | 68.2% |  | ​ |

Sales and marketing expenses increased by $3.9 million, or 65.8%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily driven by increases in personnel cost and benefits of $2.7 million associated with increases in sales and sales personnel and an increase in demand generation costs of $0.9 million due to investments made to promote sales growth.

### General and administrative

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| General and administrative |  | $34,640 | $5,242 | $29,398 | 560.8% |
| Percentage of revenue | ​ | 278.4% | 60.5% |  | ​ |

General and administrative expenses increased by $29.4 million, or 560.8%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase is primarily due to an increase in stock-based compensation expense of $16.3 million due to the additional awards granted and the performance condition for certain restricted stocks units being achieved in connection with the Closing of the Business Combination. We began to recognize expense for those awards upon the Closing of the Business Combination. In addition to stock-based compensation, the increase was primarily driven by increased personnel costs of $6.6 million due to investments made to scale up our back-office support and executive functions and personnel costs with regards to our CEO transition, recruiting expense of $1.8 million, increased consulting and professional services of $3.6 million and other general and administrative costs incremental to being a publicly traded company of $1.0 million.

### Loss from operations

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Loss from operations |  | $(53,748) | $(24,509) | $(29,239) | 119.3% |
| Percentage of revenue | ​ | (432.0)% | (282.7)% |  | ​ |

Loss from operations increased by $29.2 million, or 119.3%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily a result of increases in operating expenses of $36.5 million partially offset by an increase in gross profit of $7.3 million. The increase in gross profit was primarily due to higher volume sales and lower cost of product revenue.

### Interest expense

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Interest expense |  | $(638) | $(5) | $(633) | 12,660.0% |
| Percentage of revenue | ​ | (5.1)% | (0.1)% |  | ​ |

Interest expense increased by $0.6 million, or 12,660.0%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was driven by stated interest expense and amortization of debt issuance costs in connection with convertible notes that were issued after the first quarter of 2020.

### Other income (expense), net

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Other income (expense), net |  | $(631) | $(29) | $(602) | 2,075.9% |
| Percentage of revenue | ​ | (5.1)% | (0.3)% |  | ​ |

Other expense increased by $0.6 million, or 2,075.9%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was driven primarily by an increase of investment losses of $0.5 million.

### Net loss

*(in thousands)*

| ​ ​ | ​ ​ ​ | ​ ​ ​ Three months ended March 31, 2021 ​ | ​ ​ ​ ​ 2020 ​ | ​ ​ ​ ​ Change | ​ ​ ​ ​ ​ ​ % Change |
| --- | --- | ---: | ---: | ---: | ---: |
| Net loss |  | $(690) | $(24,354) | $23,664 | (97.2)% |
| Percentage of revenue | ​ | (5.5)% | (280.9)% |  | ​ |

Net loss decreased by $23.7 million, or 97.2%, for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. This increase was primarily a result of a higher operating loss of $29.3 million offset by the gain for the change in the fair value of the warrant liabilities $54.1 million. The warrant liabilities were recorded as part of the business combination and therefore did not exist in the prior year.

### Liquidity and Capital Resources

Since our inception, our primary sources of liquidity are cash flows from operations and issuances of preferred stock and convertible notes. In addition, on February 12, 2021, we completed the Business Combination, and as a result we received gross proceeds of approximately $589 million. Our primary uses of liquidity are operating expenses, working capital requirements and capital expenditures. Cash flows from operations have been historically negative as we continue to develop new products and services and increase our sales and marketing efforts. We expect to be cash flow negative on an annual basis, although we may have quarterly results where cash flows from operations are positive.

We expect to continue to incur net losses in the short term, as we continue to invest in research and development of our products and invest in the sales and marketing and expand into new markets and verticals.

We expect that the funds raised in connection with the Business Combination and cash flows from operations will be sufficient to meet our liquidity, capital expenditure, and anticipated working capital requirements and fund our operations for at least the next 12 months. We expect to use the funds raised in connection with the Business Combination to scale our sales and marketing capabilities, develop new products and services, and for working capital and general corporate purposes.

Our cash and cash equivalents and investment in marketable securities balance as of March 31, 2021 was $545.3 million. Our future capital requirements may vary from those currently planned and will depend on various factors, including our rate of revenue growth and the timing and extent of spending on strategic business initiatives.

### Cash flows

### Comparison of the period for the three months ended March 31, 2021 and March 31, 2020

The following table summarizes our sources and uses of cash for the three months ended March 31, 2021 and March 31, 2020:

*(in thousands)*

| ​ ​ ​ ​ ​ | ​ ​ Three months ended March 31, 2021 | ​ ​ ​ ​ 2020 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(63,427) | $(19,670) |
| Net cash used in investing activities | ​ (528,197) | ​ (480) |
| Net cash provided by financing activities | ​ 550,268 | ​ 154 |
| Net decrease in cash and cash equivalents | $(41,356) | $(19,996) |

### Cash flows used in operating activities

Net cash flows used in operating activities represent the cash receipts and disbursements related to our activities other than investing and financing activities. We expect cash provided by financing activities will continue to be our primary source of funds to support operating needs and capital expenditures for the foreseeable future.

Net cash used in operating activities increased by $43.8 million, or 222.5%, to $63.4 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase in net cash used in operating activities for the three months ended March 31, 2021 compared with the three months ended March 31, 2020 was due to a $10.9 million increase in inventory levels resulting from increased inventory purchases and a $4.6 million increase in prepaid expenses and other assets to be used in operations, as well as a $14.9 million decrease in accounts payable and accrued expenses due to the timing of expenses and payments, a $35.8 million decrease in adjustments to reconcile net loss partially offset by $23.7 million decrease in net losses.

### Cash flows used in investing activities

Net cash used in investing activities increased by $527.7 million from $0.5 million to $528.2 million for the three months ended March 31, 2021 compared to the three months ended March 31, 2020. The increase was primarily due to the investment activity for the funds received from the Business Combination.

### Cash flows provided by financing activities

For the three months ended March 31, 2021, net cash provided by financing activities was $550.3 million compared with $0.2 million for the three months ended March 31, 2020. This increase of $550.1 million was primarily due to net proceeds from the Business Combination of $547.8 million and proceeds from the exercise of stock options of $6.3 million partially offset by our $4.4 million loan repayment under the Paycheck Protection Program.

### Contractual Obligations

As of March 31, 2021, our contractual obligations were as follows:

*(in thousands)*

| ​ ​ | ​ ​ Total | ​ ​ ​ \< 1 year | ​ ​ ​ 1-3 Years | ​ ​ ​ 3-5 Years | ​ ​ ​ \> 5 years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Operating leases | $16,095 | $1,360 | $3,936 | $3,945 | $6,854 |
| Purchase obligations (1) | ​ 156,061 | ​ 53,040 | ​ 103,021 | ​ — | ​ — |
| Total contractual obligations | $172,156 | $54,400 | $106,957 | $3,945 | $6,854 |

(1) Purchase obligations include all legally binding contracts and relate to firm commitments for inventory purchases. Our purchase obligations are related to a contract for a key inventory component in our manufacturing process. Purchase orders that are not binding agreements are excluded from the table above.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management's discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about items that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Except as described in Note 2, “Summary of Significant Accounting Policies – Recent Accounting Pronouncements Adopted” and “Summary of Significant Accounting Policies – Recent Accounting Pronouncement Issued but Not Yet Adopted,” to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, there have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in our Annual Report on Form 10-K.

### Recently Adopted Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 in our condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q.

### Emerging Growth Company

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or revised accounting standards that may be issued by FASB or the SEC either (i) within the same periods as those otherwise applicable to non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption for complying with new or revised accounting standards within the same time periods as private companies. Accordingly, the information contained in this report may be different than the information you receive from other public companies.

We also intend to take advantage of some of the reduced regulatory and reporting requirements of emerging growth companies pursuant to the JOBS Act so long as we qualify as an emerging growth company, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding non-binding advisory votes on executive compensation and golden parachute payments.

## Market risk

As filed, 935 characters.

### Interest Rate Risk

We did not have any floating rate debt as of March 31, 2021. Our cash, cash equivalents and marketable securities are comprised primarily of bank deposits and equity interests in mutual funds. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of these investments, we do not expect cash flows to be affected to any significant degree by a sudden change in market interest rates.

### Foreign Exchange Risk

We operate our business primarily within the United States and currently execute the majority of our transactions in U.S. dollars. We have not utilized hedging strategies with respect to such foreign exchange exposure. This limited foreign currency translation risk is not expected to have a material impact on our condensed consolidated financial statements.

## Controls and procedures

As filed, 6,589 characters.

### Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company’s reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer concluded that, solely due to the Company’s restatement of its financial statements to reclassify the Company’s warrants as described below and in Amendment No. 1 to our Annual Report on Form 10-K/A for the year ended December 31, 2020 filed on May 12, 2021, our disclosure controls and procedures were not effective as of March 31, 2021.

### Material Weakness in Internal Control over Financial Reporting

As previously disclosed in our Amendment No. 1 to our Annual Report on Form 10-K/A for the year ended December 31, 2020, we identified a material weakness in our internal controls over financial reporting related to inaccurate accounting for public warrants and private placement warrants issued in connection with our initial public offering. Notwithstanding this material weakness, management has concluded that our unaudited financial statements included in this Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.

Our internal control over financial reporting did not detect the proper accounting and reporting for our public warrants and private placement warrants issued in connection with the Company’s initial public offering in May 2020. Management identified this error when the SEC issued a Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”) dated April 12, 2021 (the “SEC Staff Statement”). The SEC Staff Statement addresses certain accounting and reporting considerations related to warrants of a kind similar to those we issued in connection with our initial public offering in May 2020. This control deficiency resulted in the Company having to restate its audited consolidated financial statements contained in its Annual Report on Form 10-K for the year ended December 31, 2020 and if not remediated, could result in a material misstatement to future annual or interim consolidated financial statements that would not be prevented or detected. Accordingly, management has determined that this control deficiency constitutes a material weakness.

### Plan for Remediation of the Material Weakness in Internal Control over Financial Reporting

In response to this material weakness, the Company’s management has expended, and will continue to expend, a substantial amount of effort and resources for the remediation and improvement of our internal control over financial reporting. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements and other literature for all significant or unusual transactions, we are improving these processes to ensure that the nuances of such transactions are effectively evaluated in the context of the increasingly complex accounting standards. Our plans at this time include acquiring enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we may consult regarding the application of complex accounting transactions. Our remediation plan can only be accomplished over time and will be continually reviewed to determine that it is achieving its objectives. This is no assurance that these initiatives will ultimately have the intended effects.

### Changes in Internal Control over Financial Reporting

Other than the changes made to remediate the material weakness described above, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitations on the Effectiveness of Disclosure Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and implemented, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues within a company are detected. The inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

## Risk factors

As filed, 431 characters.

Our business, results of operations and financial condition are subject to various risks and uncertainties including the risk factors found under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, filed with the SEC on March 29, 2021 , as amended on May 12, 2021 (the “2020 Annual Report on Form 10-K). There have been no material changes to the risk factors described in the 2020 Annual Report on Form 10-K.

Filed May 17, 2021.
Source: SEC EDGAR, the filing index for accession 0001558370-21-007403. Last ingested by Listed: Nov 14, 2026, 23:40 ET. No prices; not investment advice.
